FRX Forest Road Acquisition Corp

Forest Laboratories, Inc. (NYSE: FRX) (“Forest”) today announced that the preliminary report of IVS Associates, Inc., the independent inspector of elections for the Company’s Annual Meeting, confirms that all ten of Forest’s Board nominees were elected by a substantial majority.

Based on the IVS report of the preliminary voting results, the ten Company nominees were elected to the Forest Board of Directors, each receiving more than a majority of all outstanding shares. Over 226 million votes, or approximately 98% of the votes cast in the election, were voted for each of the six Forest nominees that had not been contested. With regard to the four contested seats, the Forest nominees were elected by wide margins. Mr. Goodman and Mr. Solomon received over 169 million and 165 million votes, respectively, and Messrs. Goldwasser and Salans each received over 152 million votes for their election.

According to the inspector’s report, Icahn nominee Richard Mulligan received only 70.5 million votes in support of his election and Alex Denner, the Icahn candidate with the second highest total, received less than 49 million votes. Therefore, the margin of victory for the contested Forest nominees was 81 million votes with respect to Mr. Mulligan and 103 million votes with respect to Mr. Denner. Messrs. Bebchuk and Ende received only 42.1 million and 33.5 million votes in favor of their election, respectively. As of the 2011 Annual Meeting record date, the Icahn group held approximately 19.9 million Forest shares.

The inspector’s preliminary report also indicates that Forest shareholders approved the advisory vote on executive compensation, supported an annual frequency for the advisory vote on executive compensation, and ratified the appointment of BDO USA, LLP as the Company’s independent registered public accountant.

Howard Solomon, Chairman and Chief Executive Officer of Forest, said, “We are pleased to receive this positive news confirming the results of our ten nominees today as we launch Dailresp and Viibryd with our field sales organization. This is an important week as we move forward with two of the ‘Next Nine’ products in our late-stage pipeline. We expect these high-potential products to help drive growth and diversify revenues in the years ahead.”

Based on the inspector’s preliminary report, shareholders representing more than 231 million shares, or 83.1% of the Company's issued and outstanding common stock as of the record date, either voted by proxy or in person at the meeting. The preliminary vote count is subject to review, challenge and official certification, but is not expected to change materially, if at all.

Based on the report provided by IVS, the preliminary results were as follows:

Preliminary Voting Results –August 22, 2011

                      Election of Directors         For         Withheld

Forest Nominees:

                    Howard Solomon         165,349,211         4,623,743 Nesli Basgoz, M.D.         227,451,746         3,615,456 Christopher J. Coughlin         226,635,822         4,431,380 Dan L. Goldwasser         152,002,769         1,617,812 Kenneth E. Goodman         169,301,063         671,891 Gerald M. Lieberman         227,425,851         3,641,351 Lawrence S. Olanoff         226,222,145         4,845,057 Lester B. Salans         152,935,444         685,137 Brenton L. Saunders         227,430,702         3,636,500 Peter J. Zimetbaum         227,436,483         3,630,719

Icahn Nominees:

                    Alexander J. Denner         48,928,220         28,518,401 Richard Mulligan         70,539,256         6,907,365 Lucian A. Bebchuk         42,126,141         1,968,107 Eric J. Ende         33,485,948         27,608,300   Advisory Vote on Executive Compensation For         Against         Abstain 170,391,984         59,879,803         795,426   Frequency of Advisory Vote on Executive Compensation 1 Year       2 Years       3 years       Abstain 213,927,107       748,048       15,498,979       893,078   Auditor Ratification For       Against       Abstain 229,586,578       1,466,628       629,430

Forward Looking Information

Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, changes in laws and regulations affecting the healthcare industry and the risk factors listed from time to time in Forest Laboratories’ Annual Reports on Form 10-K (including the Annual Report on Form 10-K for the fiscal year ended March 31, 2011), Quarterly Reports on Form 10-Q, and any subsequent SEC filings.